to support the development, validation, and routine determination of HRD status in cancer patients.
Highly multiplexed, biosynthetic DNA, RNA and ctDNA reference materials for NGS-based assays designed to analyze hematologic malignancies such as Myeloid Leukemia and Lymphoma.